Reata Pharmaceuticals Stock Current Valuation
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Valuation analysis of Reata Pharmaceuticals helps investors to measure Reata Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Reata Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Reata Pharmaceuticals is based on 3 months time horizon. Increasing Reata Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Reata Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reata Stock. However, Reata Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 109.67 | Real 87.46 | Hype 109.67 | Naive 113.45 |
The real value of Reata Stock, also known as its intrinsic value, is the underlying worth of Reata Pharmaceuticals Company, which is reflected in its stock price. It is based on Reata Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Reata Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Reata Pharmaceuticals helps investors to forecast how Reata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reata Pharmaceuticals more accurately as focusing exclusively on Reata Pharmaceuticals' fundamentals will not take into account other important factors: Reata Pharmaceuticals Company Current Valuation Analysis
Reata Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Reata Pharmaceuticals Current Valuation | 6.4 B |
Most of Reata Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Reata Pharmaceuticals has a Current Valuation of 6.4 B. This is 55.41% lower than that of the Pharmaceuticals sector and 37.86% higher than that of the Health Care industry. The current valuation for all United States stocks is 61.48% higher than that of the company.
Reata Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reata Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics of similar companies.Reata Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Reata Fundamentals
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X | |||
| Price To Sales | 414.73 X | |||
| Revenue | 2.22 M | |||
| Gross Profit | (167.63 M) | |||
| EBITDA | (269.02 M) | |||
| Net Income | (311.9 M) | |||
| Cash And Equivalents | 481.47 M | |||
| Cash Per Share | 13.19 X | |||
| Total Debt | 119.46 M | |||
| Debt To Equity | 2.08 % | |||
| Current Ratio | 10.60 X | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | (204.27 M) | |||
| Short Ratio | 2.81 X | |||
| Earnings Per Share | (2.62) X | |||
| Target Price | 172.45 | |||
| Number Of Employees | 321 | |||
| Beta | 1.42 | |||
| Market Capitalization | 6.57 B | |||
| Total Asset | 514.49 M | |||
| Retained Earnings | (1.57 B) | |||
| Working Capital | 338.81 M | |||
| Current Asset | 87.28 M | |||
| Current Liabilities | 59.63 M | |||
| Z Score | 27.78 | |||
| Net Asset | 514.49 M |
About Reata Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reata Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |